Leap Therapeutics (LPTX)

• Market cap: $17M
• 1 day: -2.91%
• 5 days: 4.83%
• 1 month: 2.47%
• 3 months: 4.83%
• 6 months: -86.11%
• Year to date: -87.27%
• 1 year: -81.37%
• 5 years: -98.38%
• 10 years: -99.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Employees: 52

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

16% more call options, than puts

Call options by funds: $22K | Put options by funds: $19K

10.0% less ownership

Funds ownership: 50.46% [Q4 2024] → 40.46% (-10.0%) [Q1 2025]

21% less funds holding

Funds holding: 57 [Q4 2024] → 45 (-12) [Q1 2025]

36% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 14

52% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 23

91% less capital invested

Capital invested by funds: $55.6M [Q4 2024] → $5.09M (-$50.5M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]